Bictegravir sodium (BioDeep_00000839771)
代谢物信息卡片
Bictegravir sodium
化学式: C21H17F3N3NaO5 (471.10179480000005)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)[O-])C(=O)NCC5=C(C=C(C=C5F)F)F.[Na+]
InChI: /q
描述信息
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:172961
- KEGGdrug: D10910
- PubChem: 102593990
- ChEMBL: CHEMBL3989867
- CAS: 1807988-02-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jen-Yu Hsu, Hsin-Yun Sun, Ling-Ya Chen, Sui-Yuan Chang, Yu-Chung Chuang, Yu-Shan Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
Journal of global antimicrobial resistance.
2024 Mar; 36(?):426-435. doi:
10.1016/j.jgar.2023.10.012. [PMID: 37923129] - Lin Gan, Xiaoxin Xie, Yanhua Fu, Yebing Song, Chunli Song, Tingting Ren, Hai Long. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
Expert review of anti-infective therapy.
2023 Dec; ?(?):1-7. doi:
10.1080/14787210.2023.2292544. [PMID: 38058002] - Yinghua Wei, Jin Li, Ruhong Xu, Li Wen, Yiming Deng, Lixia He, Huijun Zhong, Yanhao Wang. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Chinese medical journal.
2023 Nov; ?(?):. doi:
10.1097/cm9.0000000000002907. [PMID: 37914678] - Alessandro Lazzaro, Diana Bianchini, Elio Gentilini Cacciola, Ivano Mezzaroma, Mario Falciano, Carolina Andreoni, Caterina Fimiani, Letizia Santinelli, Luca Maddaloni, Ginevra Bugani, Giancarlo Ceccarelli, Claudio Maria Mastroianni, Gabriella d'Ettorre. Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
Viruses.
2023 05; 15(6):. doi:
10.3390/v15061222. [PMID: 37376522] - Angelica Perna, Maria A Carleo, Silvia Mascolo, Alessandra Guida, Marcella Contieri, Carmine Sellitto, Eleonora Hay, Paolo De Blasiis, Angela Lucariello, Germano Guerra, Alfonso Baldi, Antonio De Luca, Paolo Maggi, Vincenzo Esposito. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
AIDS (London, England).
2023 03; 37(4):561-570. doi:
10.1097/qad.0000000000003455. [PMID: 36504092] - Anchalee Avihingsanon, Ploenchan Chetchotisakd, Sasisopin Kiertiburanakul, Winai Ratanasuwan, Krittaecho Siripassorn, Khuanchai Supparatpinyo, Hal Martin, Hui Wang, TinHung Wong, Hsiu Yin Wang. Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
HIV medicine.
2023 03; 24(3):290-300. doi:
10.1111/hiv.13386. [PMID: 36912172] - Nicola Squillace, Elena Ricci, Paolo Maggi, Lucia Taramasso, Barbara Menzaghi, Giuseppe Vittorio De Socio, Stefania Piconi, Benedetto Maurizio Celesia, Giancarlo Orofino, Eleonora Sarchi, Giovanni Francesco Pellicanò, Filomena Simeone, Laura Valsecchi, Alessandra Bandera, Giovanni Cenderello, Letizia Attala, Goffredo Angioni, Katia Falasca, Antonio Cascio, Olivia Bargiacchi, Antonio Di Biagio, Paolo Bonfanti. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
PloS one.
2023; 18(8):e0289132. doi:
10.1371/journal.pone.0289132. [PMID: 37556481] - Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L D'Antoni, Christiana Blair, Susan K Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R McNicholl, Joel Gallant. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
HIV medicine.
2023 01; 24(1):27-36. doi:
10.1111/hiv.13319. [PMID: 35527425] - Thomas Heseltine, Elen Hughes, Jean Mathew, Scott Murray, Saye Khoo. The effect of changing to Bictegravir on lipids using real world data: A brief report.
Journal of clinical pharmacy and therapeutics.
2022 Dec; 47(12):2182-2187. doi:
10.1111/jcpt.13789. [PMID: 36324275] - Kenza Ngono Ayissi, Jennifer Gorwood, Laura Le Pelletier, Christine Bourgeois, Carine Beaupère, Martine Auclair, Roberta Foresti, Roberto Motterlini, Michael Atlan, Aurélie Barrail-Tran, Roger Le Grand, Delphine Desjardins, Bruno Fève, Olivier Lambotte, Jacqueline Capeau, Véronique Béréziat, Claire Lagathu. Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.
Cells.
2022 06; 11(11):. doi:
10.3390/cells11111841. [PMID: 35681536] - Jennifer Lagoutte-Renosi, Mylène Flammang, Didier Ducloux, Jamal Bamoulid, Pierre-Yves Royer, Quentin Lepiller, Anne-Laure Clairet, Siamak Davani, Patrice Muret. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Journal of chemotherapy (Florence, Italy).
2022 May; 34(3):199-202. doi:
10.1080/1120009x.2021.1940436. [PMID: 34180378] - Engie Salama, Lucas Hill, Nimish Patel, Brookie M Best, Jeremiah D Momper. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Journal of acquired immune deficiency syndromes (1999).
2021 12; 88(4):389-392. doi:
10.1097/qai.0000000000002765. [PMID: 34285156] - Thibaut Gelé, Antoine Chéret, Alicia Castro Gordon, Lionelle Nkam, Valérie Furlan, Coralie Pallier, Pierre-Hadrien Becker, Pilartxo Catalan, Cécile Goujard, Anne-Marie Taburet, Jacques Gasnault, Hélène Gouget, Aurélie Barrail-Tran. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
The Journal of antimicrobial chemotherapy.
2021 11; 76(12):3280-3285. doi:
10.1093/jac/dkab334. [PMID: 34508640] - Bo-Huang Liou, Chih-Ning Cheng, Ya-Ting Lin, Yu-Jou Lin, Yu-Chung Chuang, Kuan-Yin Lin, Wen-Chun Liu, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Chien-Ching Hung. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Journal of the International AIDS Society.
2021 11; 24(11):e25844. doi:
10.1002/jia2.25844. [PMID: 34822220] - Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, Javier Martinez-Picado, Mackenzie L Cottrell, Pere Domingo, Ivan Chivite, Eugenia Negredo, Amanda Schauer, Brian Van Horne, Sandra Morenilla, Víctor Urrea, Ana Silva-Klug, Sofía Scévola, Benito Garcia, Angela D M Kashuba, Daniel Podzamczer. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 10; 73(7):e1991-e1999. doi:
10.1093/cid/ciaa1416. [PMID: 32945851] - M Gutiérrez-Lorenzo, D Rubio-Calvo, J Urda-Romacho. [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
2021 Aug; 34(4):315-319. doi:
10.37201/req/148.2020. [PMID: 34032111] - Paul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoit Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M Brainard, Hal Martin. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 07; 73(2):e485-e493. doi:
10.1093/cid/ciaa988. [PMID: 32668455] - Emma Touizer, Aljawharah Alrubayyi, Chloe Rees-Spear, Natasha Fisher-Pearson, Sarah A Griffith, Luke Muir, Pierre Pellegrino, Laura Waters, Fiona Burns, Sabine Kinloch, Sarah Rowland-Jones, Ravindra K Gupta, Richard Gilson, Dimitra Peppa, Laura E McCoy. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
The lancet. HIV.
2021 06; 8(6):e317-e318. doi:
10.1016/s2352-3018(21)00099-0. [PMID: 34087093] - Gianmaria Baldin, Arturo Ciccullo, Francesca Lombardi, Anna D'Angelillo, Alex Dusina, Arianna Emiliozzi, Damiano Farinacci, Davide Moschese, Chiara Picarelli, Alberto Borghetti, Simona Di Giambenedetto. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
AIDS research and human retroviruses.
2021 06; 37(6):429-432. doi:
10.1089/aid.2020.0219. [PMID: 33280486] - Felix Stader, Perrine Courlet, Laurent A Decosterd, Manuel Battegay, Catia Marzolini. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
Clinical pharmacology and therapeutics.
2021 04; 109(4):1025-1029. doi:
10.1002/cpt.2178. [PMID: 33521960] - Subhra Mandal, Pavan Kumar Prathipati, Shawnalyn W Sunagawa, Christopher J Destache. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Antimicrobial agents and chemotherapy.
2021 03; 65(4):. doi:
10.1128/aac.02320-20. [PMID: 33526487] - Elena Bekerman, Stephanie Cox, Darius Babusis, Federico Campigotto, Moupali Das, Dan H Barouch, Tomas Cihlar, Christian Callebaut. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
The Journal of antimicrobial chemotherapy.
2021 02; 76(3):692-698. doi:
10.1093/jac/dkaa476. [PMID: 33202006] - Rima K Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Aiyappa Parvangada, Hal Martin, Sean Collins, Kirsten L White. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Journal of acquired immune deficiency syndromes (1999).
2020 11; 85(3):363-371. doi:
10.1097/qai.0000000000002454. [PMID: 32701823] - Thibaut Gelé, Hélène Gouget, Valérie Furlan, Pierre-Hadrien Becker, Anne-Marie Taburet, Olivier Lambotte, Aurélie Barrail-Tran. Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
Antimicrobial agents and chemotherapy.
2020 10; 64(11):. doi:
10.1128/aac.00895-20. [PMID: 32868324] - Collins C Iwuji, Duncan Churchill, Stephen Bremner, Nicky Perry, Ye To, Debbie Lambert, Chloe Bruce, Laura Waters, Chloe Orkin, Anna Maria Geretti. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
BMC infectious diseases.
2020 Jul; 20(1):524. doi:
10.1186/s12879-020-05240-y. [PMID: 32689975] - Raúl Rigo-Bonnin, Juan Manuel Tiraboschi, Marta Álvarez-Álvarez, Gloria Ainara Pérez-Fernández, Mercedes Sanjuás-Iglesias, Sofía Scévola, Jordi Niubó, Sebastián Videla, Daniel Podzamczer. Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2020 Jun; 185(?):113250. doi:
10.1016/j.jpba.2020.113250. [PMID: 32199329] - Perrine Courlet, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini, Eva Choong, Chantal Csajka, Huldrych F Günthard, Pascal André, Thierry Buclin, Vincent Desfontaine, Laurent Arthur Decosterd. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Journal of mass spectrometry : JMS.
2020 Jun; 55(6):e4506. doi:
10.1002/jms.4506. [PMID: 32160389] - Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, Jordi Niubo, Paula Prieto, Maria Saumoy, Sujan Dilly Penchala, Benito Garcia, Cristina Padilla, Sebastian Videla, Daniel Podzamczer. Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56).
The Journal of infectious diseases.
2020 04; 221(9):1425-1428. doi:
10.1093/infdis/jiz624. [PMID: 31784745] - Hélène Gouget, Gaëlle Noé, Aurélie Barrail-Tran, Valérie Furlan. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
Journal of pharmaceutical and biomedical analysis.
2020 Mar; 181(?):113057. doi:
10.1016/j.jpba.2019.113057. [PMID: 31962247] - J Zeuli, S Rizza, R Bhatia, Z Temesgen. Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Drugs of today (Barcelona, Spain : 1998).
2019 Nov; 55(11):669-682. doi:
10.1358/dot.2019.55.11.3068796. [PMID: 31840682] - Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L Stephens, Edwin DeJesus, Hui Wang, Rima K Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Journal of acquired immune deficiency syndromes (1999).
2019 11; 82(3):321-328. doi:
10.1097/qai.0000000000002137. [PMID: 31609930] - Quentin Le Hingrat, Gilles Collin, Minh Lê, Gilles Peytavin, Benoit Visseaux, Mélanie Bertine, Roland Tubiana, Marina Karmochkine, Nadia Valin, Fidéline Collin, Adrien Lemaignen, Louis Bernard, Florence Damond, Sophie Matheron, Diane Descamps, Charlotte Charpentier. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019 08; 69(4):657-667. doi:
10.1093/cid/ciy940. [PMID: 30383215] - Hans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, Helmut Albrecht, Paul E Sax, Franco Maggiolo, Catherine Creticos, Claudia T Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana Brainard, Hal Martin. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
The lancet. HIV.
2019 06; 6(6):e364-e372. doi:
10.1016/s2352-3018(19)30080-3. [PMID: 31068272] - David A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie A Thompson, Cynthia Brinson, Debbie Hagins, Moti N Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana Brainard, Hal Martin. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
The lancet. HIV.
2019 06; 6(6):e355-e363. doi:
10.1016/s2352-3018(19)30077-3. [PMID: 31068270] - Pavan Kumar Prathipati, Subhra Mandal, Christopher J Destache. Development and validation of LC-MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study.
Biomedical chromatography : BMC.
2019 Feb; 33(2):e4379. doi:
10.1002/bmc.4379. [PMID: 30178512] - Eric S Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K Rockstroh, Jean-Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
The lancet. HIV.
2018 07; 5(7):e347-e356. doi:
10.1016/s2352-3018(18)30091-2. [PMID: 29925490] - Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
The lancet. HIV.
2018 07; 5(7):e357-e365. doi:
10.1016/s2352-3018(18)30092-4. [PMID: 29925489] - Josep M Llibre, Hortensia Álvarez, Miguel Yzusqui. Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review.
AIDS reviews.
2018; 20(3):158-170. doi:
10.24875/aidsrev.18000006. [PMID: 30264825] - Joel Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S Daar, David Wohl, Jürgen Rockstroh, Xuelian Wei, Joseph Custodio, Kirsten White, Hal Martin, Andrew Cheng, Erin Quirk. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Lancet (London, England).
2017 Nov; 390(10107):2063-2072. doi:
10.1016/s0140-6736(17)32299-7. [PMID: 28867497] - Paul E Sax, Anton Pozniak, M Luisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet (London, England).
2017 Nov; 390(10107):2073-2082. doi:
10.1016/s0140-6736(17)32340-1. [PMID: 28867499] - Joel E Gallant, Melanie Thompson, Edwin DeJesus, Gene W Voskuhl, Xuelian Wei, Heather Zhang, Kirsten White, Andrew Cheng, Erin Quirk, Hal Martin. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
Journal of acquired immune deficiency syndromes (1999).
2017 05; 75(1):61-66. doi:
10.1097/qai.0000000000001306. [PMID: 28196003] - Paul E Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Julie Peloquin, Xuelian Wei, Kirsten White, Andrew Cheng, Hal Martin, Erin Quirk. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
The lancet. HIV.
2017 04; 4(4):e154-e160. doi:
10.1016/s2352-3018(17)30016-4. [PMID: 28219610]